NBIX – neurocrine biosciences, inc. (US:NASDAQ)
Stock Stats
News
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
Form 8-K NEUROCRINE BIOSCIENCES For: Dec 20
Form 4 NEUROCRINE BIOSCIENCES For: Dec 17 Filed by: ROBERTS EIRY
Form 4 NEUROCRINE BIOSCIENCES For: Dec 17 Filed by: Delaet Ingrid
Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid
Form 4 NEUROCRINE BIOSCIENCES For: Nov 29 Filed by: Onyia Jude
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.